[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630759":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":10,"centralContacts":36,"locations":42,"responsibleParty":69,"collaborators":71,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":10,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":10,"enrollmentInfo":87,"targetDuration":10,"studyType":90,"phases":10,"briefSummary":91,"conditions":92,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Research Center of Periodontal-Systemic Interactions","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Hepatitis B+D - Bulevirtide Treatment",null,"Adult patients diagnosed with hepatitis B and D co-infection who are receiving bulevirtide therapy as part of their routine clinical management. Participants will undergo oral-periodontal clinical examination, oral cavity photography, and collection of saliva and gingival crevicular fluid for analysis of inflammatory biomarkers at baseline and after 6 months.",[13],"Drug: Bulevirtide",{"label":15,"type":10,"description":16,"interventionNames":17},"Hepatitis B+D - No Bulevirtide Treatment","Adult patients diagnosed with hepatitis B and D co-infection who are not receiving bulevirtide therapy. Participants will undergo oral-periodontal clinical examination, oral cavity photography, and collection of saliva and gingival crevicular fluid for analysis of inflammatory biomarkers at baseline and after 6 months.",[18],"Other: No intervention",{"label":20,"type":10,"description":21,"interventionNames":22},"Healthy Control Group","Systemically healthy adult individuals without hepatitis B or D infection, recruited from the Periodontology Clinic. Participants will undergo oral-periodontal clinical examination and collection of saliva and gingival crevicular fluid for comparison of periodontal clinical parameters and inflammatory biomarkers with the hepatitis B+D groups.",[18],[24,29,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"DRUG","Bulevirtide","Bulevirtide is an entry inhibitor used for the treatment of hepatitis B and D virus co-infection. In this observational study, patients receiving bulevirtide therapy as part of their routine clinical care will be evaluated for oral-periodontal clinical parameters and inflammatory biomarkers in saliva and gingival crevicular fluid.",[9],{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"No intervention","Patients diagnosed with hepatitis B+D who are not receiving bulevirtide therapy and are evaluated for comparison of oral-periodontal parameters and biomarkers.",[15],{"type":6,"name":30,"description":34,"armGroupLabels":35,"otherNames":10},"Systemically healthy individuals without hepatitis B or D infection serving as the control group for comparison of oral-periodontal parameters and inflammatory biomarkers.",[20],[37],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Petra Surlin, Professor","CONTACT","0040745538483","petra.surlin@umfcv.ro",[43,60],{"facility":44,"status":45,"city":46,"state":10,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Clinical Emergency County Hospital Craiova","RECRUITING","Craiova","Romania","RO",{"type":50,"coordinates":51},"Point",[52,53],23.8,44.31667,{"lat":53,"lon":52},[56],{"name":57,"role":39,"phone":58,"phoneExt":10,"email":59},"Claudiu Ionele, Dr.","0040722238195","claudiu.ionele@umfcv.ro",{"facility":61,"status":45,"city":46,"state":10,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"University of Medicine and Pharmacy of Craiova",{"type":50,"coordinates":63},[52,53],{"lat":53,"lon":52},[66],{"name":67,"role":39,"phone":58,"phoneExt":10,"email":68},"Dorin Gheorghe, PhD","dorin.gheorghe@umfcv.ro",{"type":70,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[72,74],{"name":73,"class":6},"University of Medicine and Pharmacy Craiova",{"name":75,"class":76},"Spitalul clinic judetean de urgenta Craiova","UNKNOWN","100630759","oral-periodontal-evaluation-and-assessment-of-oral-fluid-biomarkers-in-patients-with-hepatitis-bd-100630759",false,"NCT07491848","Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D","Oral-Periodontal Evaluation and Assessment of Biomarkers in Oral Fluids in Patients With Hepatitis B+D Treated With Bulevirtide","Inclusion Criteria:\n\n* Adults (≥18 years old) capable of providing informed consent.\n* For Hepatitis B+D groups: confirmed hepatitis B and D co-infection.\n* Bulevirtide group: receiving bulevirtide therapy as prescribed.\n* No Bulevirtide group: not receiving bulevirtide.\n* For Healthy Control group: systemically healthy adults without hepatitis B or D infection.\n* Willingness to undergo oral-periodontal examination, saliva and gingival crevicular fluid collection, and oral cavity photography.\n\nExclusion Criteria:\n\n* Patients with other systemic diseases that could influence periodontal health (e.g., uncontrolled diabetes, autoimmune diseases).\n* Patients currently receiving other experimental therapies that may affect oral or systemic inflammation.\n* Pregnancy or lactation.\n* Inability or unwillingness to provide informed consent.\n* History of oral or periodontal surgery within the last 6 months that could affect measurements.",true,"ALL","18 Years",{"count":88,"type":89},25,"ESTIMATED","OBSERVATIONAL","Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.",[93,94,95],"HEPATITIS B CHRONIC","Hepatitis D","Periodontitis","2026-03-19",{"date":98,"type":99},"2026-03-25","ACTUAL",{"date":101,"type":99},"2026-02-15",{"date":103,"type":89},"2027-02-15",{"name":5,"class":6},2]